You are here
Nicole van GriekenDr van Grieken, a pathologist, presents the past, present and future status of molecular biology in tumour research. She reviews the history of technological development that has led to molecular markers, comments on how comprehensive molecular analyses is improving our understanding of tumour biology and clinical behaviour, and addresses the challenges that remain in making molecular markers useful predictive tools. She also reviews the exciting potential value of liquid biopsies for diagnosis and follow up in cancer patients.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Fuchs CS, Tabernero J, Tomášek J, Chau I, Melichar B, Safran, et al.Br J Cancer 2016;115:974-982.
Uhlik MT, Liu J, Falcon BL, Iyer S, Stewart J, Celikkaya H, et al.Cancer Res. 2016 May 1;76(9):2573-86.
Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial
Hacker UT, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer SJ, et alBr J Cancer. 2016 Apr 12;114(8):855-62